Yu Nakamura

ORCID: 0000-0003-2866-3669
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Dementia and Cognitive Impairment Research
  • Lung Cancer Treatments and Mutations
  • HER2/EGFR in Cancer Research
  • Alzheimer's disease research and treatments
  • Monoclonal and Polyclonal Antibodies Research
  • Bladder and Urothelial Cancer Treatments
  • Neuroscience and Neuropharmacology Research
  • Urinary and Genital Oncology Studies
  • Cholinesterase and Neurodegenerative Diseases
  • Cancer Immunotherapy and Biomarkers
  • Skin and Cellular Biology Research
  • PI3K/AKT/mTOR signaling in cancer
  • Sleep and related disorders
  • Schizophrenia research and treatment
  • Parkinson's Disease Mechanisms and Treatments
  • Catalytic Alkyne Reactions
  • Pelvic floor disorders treatments
  • Cyclization and Aryne Chemistry
  • Urinary Bladder and Prostate Research
  • Health Systems, Economic Evaluations, Quality of Life
  • Cellular transport and secretion
  • Neurogenesis and neuroplasticity mechanisms
  • Aluminum toxicity and tolerance in plants and animals
  • Melanoma and MAPK Pathways
  • Restless Legs Syndrome Research

Kagawa University
2015-2025

Takamatsu University
2013-2024

Matsunami General Hospital
2024

Kyorin University
2016-2024

Tokyo Metropolitan Institute of Gerontology
2024

Foundation for Biomedical Research and Innovation
2023

Kagawa University Hospital
2023

Tokyo Institute of Technology
2016-2022

Life Science Institute
2022

Tokyo Medical and Dental University
2016-2021

Significance Alzheimer’s disease (AD) involves neuron dysfunction and loss. This brain damage is thought to be caused by a small protein, the amyloid β-protein (Aβ), which forms aggregates that are neurotoxic. neurotoxicity has been explained multiple mechanisms. We reveal here new neurotoxic mechanism interaction between patient-derived Aβ assemblies, termed amylospheroids, neuron-specific Na + /K -ATPase α3 subunit. causes neurodegeneration through pre-synaptic calcium overload, explains...

10.1073/pnas.1421182112 article EN Proceedings of the National Academy of Sciences 2015-07-29

c‐Met is often overexpressed in non‐small cell lung cancer, but it remains unsolved whether its overexpression leads to activation. We used an antibody specific phospho‐c‐Met (Tyr1235) investigate activation immunohistochemically 130 surgically resected adenocarcinomas. The expression of and hepatocyte growth factor (HGF) was also investigated. Phospho‐c‐Met positive 21.5% (28/130) cases. 74.6% cases (97/130) expressed at high levels 36.1% (47/130). HGF 31.5% (41/130). correlated with ( P =...

10.1111/j.1349-7006.2007.00493.x article EN other-oa Cancer Science 2007-04-24

Most patients with non‐small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor ( EGFR ) mutations, such as deletions in exon 19 or the L858R mutation 21, respond dramatically to tyrosine kinase inhibitors (EGFR‐TKI), and their sensitivities various EGFR‐TKI have been well characterized. Our previous article showed vitro of 18 mutations EGFR‐TKI, but little information regarding other uncommon is available. First, stable transfectant Ba/F3 lines (Ba/F3‐L858R), L861Q...

10.1111/cas.12980 article EN cc-by-nc-nd Cancer Science 2016-05-30

A facile synthetic method for preparing 3-amino-2-silylaryl triflates via regioselective silylamination of 3-(triflyloxy)arynes with N-silylamines is described. Fluoride-mediated generation 3-aminobenzyne from 3-amino-2-silylphenyl triflate, easily prepared by this method, in the presence various arynophiles efficiently afforded diverse aniline derivatives, including a 5-aminocoumarin derivative, demonstrating utility aryne relay approach.

10.1021/acs.orglett.6b03304 article EN Organic Letters 2016-11-22

Enfortumab vedotin (EV) was approved for advanced urothelial carcinoma (UC) in 2021 after the EV-301 trial showed its superiority to non-platinum-based chemotherapy as later-line treatment platinum-based and immune checkpoint inhibitors including pembrolizumab. However, no study has compared EV with rechallenging (i.e., "platinum rechallenge") that setting.In total, 283 patients received pembrolizumab UC between 2018 2023. Of them, 41 25 platinum rechallenge, respectively, After excluding...

10.1111/iju.15300 article EN International Journal of Urology 2023-09-22

Abstract Gastric cancer is the second common malignant neoplasia in Japan, and its poorly differentiated form a deadly disease. To identify novel candidate oncogenes contributing to genesis, we examined copy‐number alterations 50 primary gastric cancers using an array‐based comparative genomic hybridization (array‐CGH). Many genetic changes were identified, including amplification of 13q22 locus. Several genes are located this locus, selective knockdown one for Krüppel‐like factor 12 (KLF12)...

10.1002/ijc.24538 article EN International Journal of Cancer 2009-04-27

The oxidative debenzylation of N-benzyl amides and O-benzyl ethers was promoted with high efficiency by a bromo radical formed through the oxidation bromide from alkali metal under mild conditions. This reaction provided corresponding carbonyl compounds in yields.

10.1021/ol501703y article EN Organic Letters 2014-06-30

Objective We examined whether androgen receptor splice variant 7 (AR‐V7) in circulating tumor cell(CTC)clusters can be used to predict survival patients with bone metastatic castration resistant‐prostate cancer (mCRPC) treated abiraterone or enzalutamide. Methods retrospectively enrolled 98 CRPC on enzalutamide, and investigated the prognostic value of CTC cluster detection (+ v −) AR‐V7 using a − based mRNA assay. ≤50% prostate‐specific antigen (PSA) responses, PSA progression‐free...

10.1002/pros.23501 article EN The Prostate 2018-03-05

Abstract INTRODUCTION We evaluated the efficacy and safety of brexpiprazole for treatment agitation in Alzheimer's dementia (AAD) Japanese patients. METHODS This was a phase 2/3 multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Patients with AAD were randomized to receive 1 mg/day or 2 mg/day, placebo (3:4:4) 10 weeks. RESULTS For primary endpoint (change Cohen‐Mansfield Agitation Inventory [CMAI] total score from baseline Week 10), both mg groups demonstrated...

10.1002/alz.14282 article EN cc-by Alzheimer s & Dementia 2024-10-06

To analyze the cell cycle-dependent desmin phosphorylation by Rho kinase, we developed antibodies specifically recognizing kinase-dependent of at Thr-16, Thr-75, and Thr-76. With these antibodies, was observed cleavage furrow in late mitotic Saos-2 cells. We then found that treatment interphase cells with calyculin A revealed all three sites desmin. also an antibody, which recognizes vimentin phosphorylated Ser-71 became immunoreactive after treatment. This A-induced blocked kinase inhibitor...

10.1074/jbc.274.49.34932 article EN cc-by Journal of Biological Chemistry 1999-12-01

The synthetic utility of 3-thioaryne intermediates has been demonstrated through an aryne relay approach. efficient synthesis o-silylaryl triflate-type precursors achieved by the regioselective silylthiolation 3-(triflyloxy)arynes with silyl sulfides. Various 3-thioarynes were successfully generated from these and reacted various arynophiles to afford diverse multisubstituted aryl Further derivatizations products enabled easy access novel sulfur-containing π-extended heterocycles, which...

10.1021/acs.orglett.9b01862 article EN Organic Letters 2019-06-25

Background Several studies have reported the incidence of immune-related adverse events (irAEs) as a predictor efficacy anti-programmed cell death protein 1 antibodies in patients with cancer. However, immortal time bias has not always been fully addressed these studies. In this retrospective multicenter study, we assessed association between irAEs and pembrolizumab urothelial carcinoma (UC) using time-dependent analysis, an established statistical method to minimize bias. Methods The study...

10.1136/jitc-2021-003965 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2022-02-01

<i>Background:</i> As of 2010, the rivastigmine patch was licensed for treatment Alzheimer’s disease (AD) in 64 countries. <i>Methods:</i> This 24-week, multicenter, randomized, double-blind, placebo-controlled study evaluated efficacy, safety and tolerability 5-cm<sup>2</sup> (9-mg loading dose; 4.6 mg/24 h delivery rate) 10-cm<sup>2</sup> (18-mg 9.5 Japanese patients with AD. <i>Results:</i> In primary analysis population...

10.1159/000328929 article EN cc-by-nc Dementia and Geriatric Cognitive Disorders Extra 2011-06-24

Aim To examine the efficacy of rehabilitation for elderly individuals with dementia at intermediate facilities between hospitals and home, based on policies to promote community‐based care home dehospitalization. Methods Participants were older adults newly admitted facilities. A total 158 in intervention group who claimed L ong‐ T erm C are I nsurance three consecutive months, 54 control included analysis. The interventions carried out a tailor‐made manner meet individual needs. personal...

10.1111/ggi.12080 article EN Geriatrics and gerontology international/Geriatrics & gerontology international 2013-05-06

We evaluated a handling method using tunnels to tame laboratory mice (ICR) in the context of animal welfare and ease handling. During 1-week acclimation subsequent oral administration (once per day), voluntary interaction with experimenter was much greater handled by tunnel compared those picked up tail. According rating mice, facilitated mouse during gavage saline tail In addition, showed less anxiety than open field test, but not elevated plus maze. Calculation experimental variation...

10.1292/jvms.18-0044 article EN Journal of Veterinary Medical Science 2018-01-01
Coming Soon ...